Coronary risk assessment and management options in chronic kidney disease patients prior to kidney transplantation

Current Cardiology Reviews

Volumn 5, Issue 3, 2009, Pages 177-186

  Karthikeyan, Vanji ^a   Ananthasubramaniam, Karthik ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Chronic kidney disease; Coronary angiography; Coronary artery disease; Dobutamine echocardiography; Kidney transplantation; Myocardial perfusion imaging; Renal transplantation; Risk stratification; Stress echocardiography

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; METOPROLOL; OMEGA 3 FATTY ACID; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; AUTONOMIC DYSFUNCTION; BARE METAL STENT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; ETHNICITY; EXERCISE ELECTROCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART RATE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PERIOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; STRESS ECHOCARDIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70449704662     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340309788970342     Document Type: Review

References (75)

1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System, USRDS 1996 Annual Data Report. Bethesda, MD; 1996 Contract No.: Document Number.
2. Gill JS, Ma I, Landsberg D, Johnson N, Levin A. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol 2005; 16: 808-816 (Pubitemid 41725118)
3. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589-597 (Pubitemid 32180029)
4. Kramer W, Wizemann V, Thormann J, Kindler M, Mueller K, Schlepper M. Cardiac dysfunction in patients on maintenance hemodialysis. I. The importance of associated heart diseases in determining alterations of cardiac performance. Contrib Nephrol 1986; 52: 97-109.
5. Manske CL, Thomas W, Wang Y, Wilson RF. Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. Kidney Int 1993; 44: 617-621 (Pubitemid 23265232)
6. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-165
7. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-1743 (Pubitemid 30679723)
8. Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant 2005; 20: 2207-2214 (Pubitemid 41510099)
9. Braun WE, Phillips DF, Vidt DG, et al. Coronary artery disease in 100 diabetics with end-stage renal failure. Transplant Proc 1984; 16: 603-607 (Pubitemid 14065531)
10. Margolis JR, Kannel WS, Feinleib M, Dawber TR, McNamara PM. Clinical features of unrecognized myocardial infarction - silent and symptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol 1973; 32: 1-7.
11. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 1984; 25: 653-659 (Pubitemid 14079960)
12. Rostand SG, Kirk KA, Rutsky EA. The epidemiology of coronary artery disease in patients on maintenance hemodialysis: implications for management. Contrib Nephrol 1986; 52: 34-41.
13. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354
14. Schmidt A, Stefenelli T, Schuster E, Mayer G. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis 2001; 37: 56-63. (Pubitemid 32055019)
15. Gowdak LH, de Paula FJ, Cesar LA, et al. Screening for significant coronary artery disease in high-risk renal transplant candidates. Coron Artery Dis 2007; 18: 553-558 (Pubitemid 47556387)
16. De Lima JJ, Sabbaga E, Vieira ML, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension 2003; 42: 263-268 (Pubitemid 37093471)
17. Lewis MS, Wilson RA, Walker KW, et al. Validation of an algorithm for predicting cardiac events in renal transplant candidates. Am J Cardiol 2002; 89: 847-850 (Pubitemid 34241464)
18. Rabbat CG, Treleaven DJ, Russell JD, Ludwin D, Cook DJ. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol 2003; 14: 431-439 (Pubitemid 36150867)
19. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50: e159-241.
20. Herzog CA, Marwick TH, Pheley AM, White CW, Rao VK, Dick CD. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. Am J Kidney Dis 1999; 33: 1080-1090 (Pubitemid 29252678)
21. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-1049
22. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1 (Suppl 2): 3-95.
23. Lewis MS, Wilson RA, Walker K, et al. Factors in cardiac risk stratification of candidates for renal transplant. J Cardiovasc Risk 1999; 6: 251-255
24. Vandenberg BF, Rossen JD, Grover-McKay M, Shammas NW, Burns TL, Rezai K. Evaluation of diabetic patients for renal and pancreas transplantation: noninvasive screening for coronary artery disease using radionuclide methods. Transplantation 1996; 62: 1230-1235 (Pubitemid 27008545)
25. Marwick TH, Steinmuller DR, Underwood DA, et al. Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure. Transplantation 1990; 49: 100-103 (Pubitemid 20051594)
26. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911 (Pubitemid 29197978)
27. Abe S, Yoshizawa M, Nakanishi N, et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J 1996; 131: 1137-1144 (Pubitemid 26176992)
28. Shapira OM, Bar-Khayim Y. ECG changes and cardiac arrhythmias in chronic renal failure patients on hemodialysis. J Electrocardiol 1992; 25: 273-279
29. Kannel WB, Anderson K, McGee DL, Degatano LS, Stampfer MJ. Nonspecific electrocardiographic abnormality as a predictor of coronary heart disease: the Framingham Study. Am Heart J 1987; 113: 370-376 (Pubitemid 17011297)
30. Holley JL, Fenton RA, Arthur RS. Thallium stress testing does not predict cardiovascular risk in diabetic patients with end-stage renal disease undergoing cadaveric renal transplantation. Am J Med 1991; 90: 563-570
31. Boudreau RJ, Strony JT, duCret RP, et al. Perfusion thallium imaging of type I diabetes patients with end stage renal disease: comparison of oral and intravenous dipyridamole administration. Radiology 1990; 175: 103-105
32. Lewin HC, Hachamovitch R, Harris AG, et al. Sustained reduction of exercise perfusion defect extent and severity with isosorbide mononitrate (Imdur) as demonstrated by means of technetium 99m sestamibi. J Nucl Cardiol 2000; 7: 342-353 (Pubitemid 30657737)
33. Taillefer R, Ahlberg AW, Masood Y, et al. Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol 2003; 42: 1475-1483 (Pubitemid 37267293)
34. Patel AD, Abo-Auda WS, Davis JM, et al. Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. Am J Cardiol 2003; 92: 146-151
35. Poldermans D, Fioretti PM, Boersma E, et al. Long-term prognostic value of dobutamine-atropine stress echocardiography in 1737 patients with known or suspected coronary artery disease: A single-center experience. Circulation 1999; 99: 757-762
36. Poldermans D, Arnese M, Fioretti PM, et al. Improved cardiac risk stratification in major vascular surgery with dobutamine-atropine stress echocardiography. J Am Coll Cardiol 1995; 26: 648-653
37. Poldermans D, Fioretti PM, Forster T, et al. Dobutamine stress echocardiography for assessment of perioperative cardiac risk in patients undergoing major vascular surgery. Circulation 1993; 87: 1506-1512 (Pubitemid 23133094)
38. Reis G, Marcovitz PA, Leichtman AB, et al. Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. Am J Cardiol 1995; 75: 707-710
39. Bates JR, Sawada SG, Segar DS, et al. Evaluation using dobutamine stress echocardiography in patients with insulin-dependent diabetes mellitus before kidney and/or pancreas transplantation. Am J Cardiol 1996; 77: 175-179
40. Tita C, Karthikeyan V, Stroe A, Jacobsen G, Ananthasubramaniam K. Stress echocardiography for risk stratification in patients with end-stage renal disease undergoing renal transplantation. J Am Soc Echocardiogr 2008; 21: 321-326
41. Secknus MA, Niedermaier ON, Lauer MS, Marwick TH. Diagnostic and prognostic implications of left ventricular cavity obliteration response to dobutamine echocardiography. Am J Cardiol 1998; 81: 1318-1322
42. Smart SC, Knickelbine T, Malik F, Sagar KB. Dobutamine-atropine stress echocardiography for the detection of coronary artery disease in patients with left ventricular hypertrophy. Importance of chamber size and systolic wall stress. Circulation 2000; 101: 258-263
43. Ballal RS, Secknus MA, Mehta R, Kapadia S, Lauer MS, Marwick TH. Cardiac outcomes in coronary patients with submaximum dobutamine stress echocardiography. Am J Cardiol 1997; 80: 725-729 (Pubitemid 27413580)
44. Chaowalit N, Maalouf JF, Rooke TW, Barnes ME, Bailey KR, Pellikka PA. Prognostic significance of chronotropic response to dobutamine stress echocardiography in patients with peripheral arterial disease. Am J Cardiol 2004; 94: 1523-1528 (Pubitemid 40268454)
45. Patel SJ, Srivastava A, Lingam N, Jacobsen G, Ananthasubramaniam K. Prognostic significance of submaximal negative dobutamine stress echocardiography: A 3-year follow-up study. Cardiol J 2008; 15: 237-244
46. Manske CL, Wang Y, Rector T, Wilson RF, White CW. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992; 340: 998-1002.
47. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004; 351: 2795-2804 (Pubitemid 40051903)
48. Poldermans D, Schouten O, Vidakovic R, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol 2007; 49: 1763-1769 (Pubitemid 46617863)
49. Karthikeyan V, Karpinski J, Nair RC, Knoll G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004; 4: 262-269 (Pubitemid 38248531)
50. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-620 (Pubitemid 20384319)
51. Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant 2006; 21: 1040-1045
52. Weisbord SD, Bernardini J, Mor MK, et al. The effect of coronary angiography on residual renal function in patients on peritoneal dialysis. Clin Cardiol 2006; 29: 494-497 (Pubitemid 44713782)
53. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701.
54. Mao J, Chattahi J, Karthikeyan V, Ananthasubramaniam K. Safety, feasibility, and interpretability of coronary computed tomo-graphic angiography in end stage renal disease patients on dialysis: a pilot study. J Cardiovasc Comp Tomogr 2008; 2: S9.
55. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
56. Hirsh J. Guidelines for antithrombotic therapy: Summary of the American College of Chest Physicians recommendations, 2000. 4th ed. Hamilton [Ont.]: Lewiston, NY; 2001.
57. Carvalho AC. Acquired platelet dysfunction in patients with uremia. Hematol Oncol Clin North Am 1990; 4: 129-143 (Pubitemid 20095142)
58. Jubelirer SJ. Hemostatic abnormalities in renal disease. Am J Kidney Dis 1985; 5: 219-225
59. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45: 473-484 (Pubitemid 40341326)
60. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713-1720
61. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789-1794
62. Schouten O, Bax JJ, Dunkelgrun M, Feringa HH, van Urk H, Poldermans D. Statins for the prevention of perioperative cardiovascular complications in vascular surgery. J Vasc Surg 2006; 44: 419-424 (Pubitemid 44150625)
63. Devereaux PJ, ed. The perioperative ischemic evaluation (POISE) trial: A randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. American Heart Association: Late-Breaking Trials; 2007; Orlando, FL. 2008.
64. Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ 2006; 332: 1482-1488
65. Hoeks SE, Scholte Op Reimer WJ, et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg 2007; 33: 13-19
66. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297-304.
67. Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 2004; 44: 61-67
68. Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982; 31: 103-110
69. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482
70. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD; 2004 Contract No.: Document Number.
71. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 (Pubitemid 41058323)
72. Svensson M, Schmidt EB, Jorgensen KA, Christensen JH. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebocontrolled intervention trial. Clin J Am Soc Nephrol 2006; 1: 780-786
73. Fellstrom BC, Holdaas H, Jardine AG. Why do we need a statin trial in hemodialysis patients? Kidney Int Suppl 2003; 84: S204-6.
74. Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 2004; 11: 253-264
75. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005; 20: 541-546